atai Life Sciences Announces First Subject Dosed in Phase 1 Trial of Buccal and IV VLS-01, a Synthetic Form of DMTGlobeNewsWire • 10/05/22
atai Life Sciences to Participate in October Investor Events & Host Virtual R&D DayGlobeNewsWire • 10/04/22
Atai Life Sciences N.V.'s (ATAI) CEO Florian Brand on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/15/22
atai Life Sciences Reports Second Quarter 2022 Financial Results & Business UpdateGlobeNewsWire • 08/15/22
atai Life Sciences Secures Term Loan Facility for up to $175 Million from Hercules CapitalGlobeNewsWire • 08/15/22
atai Life Sciences to Announce Second Quarter 2022 Financial Results and Business UpdateGlobeNewsWire • 08/01/22
Atai Life Sciences: Leading But Early Stage Psychedelic Therapeutics DeveloperSeeking Alpha • 07/07/22
atai Life Sciences Company Kures Therapeutics Appoints Dr. Chad Beyer as Chief Executive OfficerGlobeNewsWire • 06/30/22
atai Life Sciences' (ATAI) CEO Florian Brand on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/16/22
atai Life Sciences Reports First Quarter 2022 Financial Results and Business UpdateGlobeNewsWire • 05/16/22